Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rosetta forms diagnostics pact for lung and mesothelioma cancers:

This article was originally published in Clinica

Executive Summary

Israel's Rosetta Genomics has linked up with the NYU Medical Center in the US to develop a line of early detection diagnostic products for lung and mesothelioma cancers. The test will mainly target the 45 million population in the US that is at increased risk of lung cancer due to smoking, as well as those who have been exposed to asbestos fibres, said the Rehovot-based firm. It will use Rosetta's proprietary protocol to extract microRNAs from a simple blood draw. "MicroRNAs have been shown to hold great potential as effective biomarkers for various cancers," said partner Dr Harvey Pass, of the New York-based medical centre.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT048225

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel